Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
Agile Therapeutics (Nasdaq: AGRX) will report its second quarter 2022 financial results after market close on August 11, 2022. The company will host a live conference call at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can join the call by dialing (888) 330-2454 for domestic or (240) 789-2714 for international listeners, using Conference ID 7871426. A live webcast will also be available on their investor relations page.
- Upcoming conference call for Q2 results may indicate transparency and communication with investors.
- None.
Live Conference Call and Webcast at 4:30 p.m. ET
PRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2022 financial results after the market close on Thursday, August 11, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.
| Date | Thursday, August 11, 2022 |
| Time | 4:30 p.m. ET |
| Webcast (live and archived) | Events & Presentations |
| Dial-in numbers | (888) 330-2454 (U.S. toll-free) or (240) 789-2714 |
| Conference ID | 7871426 |
Investors interested in listening to the conference call may do so by dialing (888) 330-2454 for domestic callers or (240) 789-2714 for international callers. The Conference ID is 7871426. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.
Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.
FAQ
When will Agile Therapeutics report its second quarter 2022 financial results?
What time is Agile Therapeutics' conference call scheduled for?
How can I listen to the conference call for Agile Therapeutics' Q2 results?
Where can I find the webcast for Agile Therapeutics' Q2 financial results?
